Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5944
Source ID: NCT04272359
Associated Drug: Sulfa-Zero: Possible Benefits Of The Treatment Of New Generation Hypoglycaemic Drugs Compared To Sulphonylureas
Title: Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Acronym: Sulfa-Zero
Status: UNKNOWN
Study Results: NO
Results:
Conditions: T2DM (Type 2 Diabetes Mellitus)|Diet, Healthy|Renal Function Disorder|Albuminuria
Interventions: DRUG: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Outcome Measures: Primary: Concentration of the glyco-metabolic parameters, Evaluation of the new generation hypoglicemic drugs on Hba1c, blood glucose, lipidic profile, 12 months|Therapeutic adherence, Assessment of adherence to the doctor's prescription of new generation hypoglycaemic drugs, 12 months|Long-term diabetes complications, Evaluation of the effect of new generation hypoglycemic drugs on the long-term complications of diabetes compared to the effect obtained with sulphonylureas, 12 months | Secondary: Values of the insulin-sensitivity, Evaluation of the effect of new generation hypoglycemic drugs on the insulin secretion of diabetes compared to the effect obtained with sulphonylureas., 12 months|Therapeutic compliance, even in populations over 70 years., Evaluation of the effect of new generation hypoglycemic drugs on therapeutic adherence with respect to the effect obtained with sulphonylureas even in older subjects., 12 months|Insulin parameters after shift to new-generation hypoglycaemic therapeutic regimens, HOMA-IR and HOMA-B% insulin parameters evaluation in patients not in insulin treatment, 12 months
Sponsor/Collaborators: Sponsor: University of Milan
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 138
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2019-05-06
Completion Date: 2021-12-31
Results First Posted:
Last Update Posted: 2021-09-28
Locations: ASST FBF-Sacco P.O. Sacco/Fatebenefratelli e Oftalmico, Milano, 20157, Italy
URL: https://clinicaltrials.gov/show/NCT04272359